SENOCLEAR-T: A novel antibody-drug conjugate designed to selectively eliminate senescent immune cells and reverse immunosenescence
of circulating T-cells become senescent by age 70
Senescent T-cells are functionally exhausted but persist in circulation
Result: Chronic systemic inflammation ("inflammaging")
years of immune function decline by age 70
Vaccine efficacy drops 50-70% in elderly populations
No FDA-approved immunosenescence therapy exists
years restoration goal across multiple domains
Immunosenescence is upstream driver of multi-system aging
Restoration cascades to muscle, cognition, overall healthspan
A precision-targeted senolytic consisting of three engineered components
Anti-CD57 Humanized IgG1
Targets CD57: senescence marker on 70-85% of senescent T-cells. Specifically recognizes exhausted immune cells.
VC-PABC
Valine-Citrulline-PABC: cathepsin-B cleavable. Remains stable in bloodstream, releases payload only inside target cells.
Navitoclax (BCL-2/BCL-xL Inhibitor)
Most potent senolytic available (IC50 <1 nM). Kills senescent cells via mitochondrial apoptosis.
First therapeutic to directly target immunosenescence with unprecedented specificity and potency
| Feature | Dasatinib + Quercetin (D+Q) | Fisetin | SENOCLEAR-T |
|---|---|---|---|
| Targeting | All senescent cells | All senescent cells | CD57+ immune cells only |
| Specificity | Low | Low-Moderate | HIGH ⭐ |
| Potency | Moderate | Moderate | Very High ⭐ |
| Immune Restoration | 10-15 years est. | 10-15 years est. | 20-25 years est. ⭐ |
| Thrombocytopenia Risk | Minimal | Minimal | NONE ⭐ |
| Innovation Level | Incremental | Incremental | Breakthrough ⭐ |
We're currently conducting comprehensive computational simulations to validate our approach across diverse patient populations and treatment protocols.
View Our Testing Methodology